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Aims: The mode of action by which doxapram acts as a respiratory stimulant in 
humans is controversial. Studies in rodent models, have shown that doxapram is a 
more potent and selective inhibitor of TASK‐1 and TASK‐1/TASK‐3 heterodimer 
channels, than TASK‐3. Here we investigate the direct effect of doxapram and chi-
rally separated, individual positive and negative enantiomers of the compound, on 
both human and mouse, homodimeric and heterodimeric variants of TASK‐1 and 
TASK‐3.
Methods: Whole‐cell patch clamp electrophysiology on tsA201 cells was used to 
assess the potency of doxapram on cloned human or mouse TASK‐1, TASK‐3 and 
TASK‐2 channels. Mutations of amino acids in the pore‐lining region of TASK‐3 
channels were introduced using site‐directed mutagenesis.
Results: Doxapram was an equipotent inhibitor of human TASK‐1 and TASK‐3 
channels, compared with mouse channel variants, where it was more selective for 
TASK‐1 and heterodimers of TASK‐1 and TASK‐3. The effect of doxapram could 
be attenuated by either the removal of the C‐terminus of human TASK‐3 channels or 
mutations of particular hydrophobic residues in the pore‐lining region. These muta-
tions, however, did not alter the effect of a known extracellular inhibitor of TASK‐3, 
zinc. The positive enantiomer of doxapram, GAL‐054, was a more potent antagonist 
of TASK channels, than doxapram, whereas the negative enantiomer, GAL‐053, had 
little inhibitory effect.
Conclusion: These data show that in contrast to rodent channels, doxapram is a 
potent inhibitor of both TASK‐1 and TASK‐3 human channels, providing further 
understanding of the pharmacological profile of doxapram in humans and informing 
the development of new therapeutic agents.
K E Y W O R D S
doxapram, enantiomers, heterodimers, K2P channels, respiratory stimulant, TASK‐1 channels, TASK‐3 
channels
This is an open access article under the terms of the Creat ive Commo ns Attri bution License, which permits use, distribution and reproduction in any medium, provided the original 
work is properly cited.
© 2019 The Authors. Acta Physiologica published by John Wiley & Sons Ltd on behalf of Scandinavian Physiological Society
2 of 13 |   CUNNINGHAM et Al.
1 |  INTRODUCTION
Doxapram (1‐ethyl‐4‐(2‐morpholinoethyl)‐3,3‐diphe-
nyl‐2‐pyrrolidinone) is a central respiratory stimulant used 
clinically in the treatment of post‐operative respiratory 
depression, acute respiratory failure, chronic obstructive 
pulmonary disorder and apnoea in premature infants.1,2 
Doxapram's analeptic respiratory action is characterized by 
an increase in tidal volume and a slight increase in respira-
tory rate, when administered intravenously.3 The compound's 
mode of action has long been debated, with conflicting data 
from animal and human models.2 Recent studies propose 
a mode of action that occurs via the direct stimulation of 
peripheral chemoreceptors of type 1 cells within the carotid 
bodies and a subsequent release of catecholamines and other 
neurotransmitters.4,5 This results in the prevention or rever-
sal of central nervous system depressant or narcotic–in-
duced respiratory failure. Neurotransmitter release by type 
1 cells occurs in response to an increase in cytosolic calcium 
(Ca2+) levels, mediated by voltage‐gated calcium channels 
in response to an electrical signal causing the membrane to 
depolarize.
A number of potassium (K) channels have been identi-
fied in type 1 cells, including delayed rectifier K+‐channels, 
calcium‐activated K‐channels, HERG channels and TWIK‐
related acid‐sensitive K+‐channels (TASK).6-10 The resting 
membrane K conductance of carotid bodies, has been shown 
to be predominantly mediated by a TASK‐like current, which 
when inhibited, results in an influx of Ca2+ ions and subse-
quent membrane depolarization.11 Both TASK‐1 (KCNK3) 
and TASK‐3 (KCNK9) are expressed in the carotid body,12,13 
present as a mixture of homodimeric and heterodimeric 
TASK‐1 and TASK‐3 channels, with heterodimeric chan-
nels, the predominant form.13,14 Stimulation of chemorecep-
tors by doxapram is thought to occur via the direct inhibition 
of a TASK channel.15,16 Indeed, mice lacking either TASK‐1 
or both TASK‐1 and TASK‐3 have impaired carotid body 
function.17,18
Previous work,15 on cloned rat TASK channels, showed 
that doxapram's selectivity favoured TASK‐1 homodimeric 
channels, followed by TASK‐1/TASK‐3 heterodimeric chan-
nels and to a lesser extent TASK‐3 homodimeric channels, 
with EC50’s of 410 nM, 9 µM and 37 µM respectively. With 
a therapeutic range of 4‐5  µM for doxapram in the blood 
plasma,19 respiratory stimulation in the rat would appear 
to occur predominantly through homodimeric rat TASK‐1 
channels. The differential selectivity between the channels 
was thought to reside at the carboxy intracellular domains 
of the channels, where homology between TASK‐1 and 
TASK‐3 sequence is the least.15
Later studies from a number of groups identified, using 
molecular modelling, a common intracellular binding site 
at the pore region of rat TASK channels that was thought to 
transduce the inhibitory effects of a number of related com-
pounds, A1899, PKTHPP and doxapram.20-22 Four amino 
acids in the pore region of rat TASK‐3, Leucine (L) 122, 
Glycine (G) 236, L 239 and valine (V) 242, were shown to 
effect the efficacy of compounds such as doxapram, when 
mutated to an aspartate (D), highlighting the importance 
of this region in TASK channels for the action of these 
compound types.22 Interestingly, one of these highlighted 
amino acids, G 236 when mutated to an arginine (R) is re-
sponsible for the condition, Birk Barel mental retardation 
syndrome.23
Doxapram is a racemic compound which is comprised 
of positive (+) and negative (−) enantiomers. Galleon 
Pharmaceuticals showed that by chirally separating doxapram 
into its positive (+) (GAL‐054) and negative (−) (GAL‐053) 
enantiomers, that ventilatory stimulation was conferred by 
GAL‐054 and not GAL‐053. Moreover, the adverse events 
such as dysrhythmias, agitation and seizures, observed with 
doxapram, were only observed with GAL‐053.24-27 Phase 1 
trials with GAL‐054 in healthy volunteers, however, found 
that GAL‐054 caused hypertension, as previously seen in rat 
models.27
In this study, using electrophysiological techniques and 
heterologous cell expression systems we investigated the di-
rect effect of doxapram on human and mouse cloned homod-
imeric and heterodimeric TASK channels and a structurally 
related channel, from the TALK subfamily, TASK‐2.
Also, we further investigated the mode of action of doxa-
pram on human TASK‐3 channels, using pore specific muta-
tions and C‐terminally truncated channels.
Finally, we studied the effect of positive and negative en-
antiomers of doxapram, GAL‐054 and GAL‐053, in isolation 
on human homodimeric TASK‐1 and TASK‐3 channels. A 
preliminary account of some of these data has been reported 
previously.28
2 |  RESULTS
2.1 | Doxapram is a potent inhibitor of both 
TASK‐1 and TASK‐3 human cloned channels
Our initial experiments sought to determine the pharma-
cological profile of doxapram on homodimeric TASK‐1 
and TASK‐3 channels and a structurally related chan-
nel from the TALK subfamily, TASK‐2, using cloned 
human channels, transiently expressed in tsA201 cells 
and studied using whole‐cell patch clamp electro-
physiology. Surprisingly, unlike for cloned rat TASK 
channels,15,22 doxapram showed an increase potency 
against human TASK‐3 channels, over a range of con-
centrations (0.3‐100  µM), with a calculated 50% effec-
tive concentration (EC50) of 2.5  µM [95% CI: 1.9‐3.5] 
and a Hill slope of 0.8 [95% CI: 0.5‐1.1]  (Figure 1). 
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For human TASK‐1 channels the potent inhibitory effect 
remained similar to rodent channels, with an observed 
EC50 of 4.0 µM [95% CI: 2.1‐7.9] and a Hill slope of 0.8 
[95% CI: 0.7‐1.0] for TASK‐1 (Figure 1). Similar to ef-
fects seen with rodent channels,15 recovery from inhi-
bition of TASK‐1 by doxapram (10  µM) was slow and 
mostly incomplete, whilst for TASK‐3, recovery from 
doxapram (10  µM) inhibition was faster and more com-
plete. By contrast, doxapram (10 µM) had little effect on 
currents through TASK‐2 channels (Figure 1E,F). Acute 
application of 10 µM doxapram to WT TASK‐2 resulted 
in an inhibition of 7% [95% CI: −3 to 16; n = 6], which 
was significantly less (P  <  .05, one‐way ANOVA, fol-
lowed by a Dunnett's multiple comparisons test, [95% CI 
of difference: 35‐61]) than the 55% inhibition [95% CI: 
45‐65; n = 8] seen for TASK‐1 channels and also signifi-
cantly less [P < .05, 95% CI of difference: 48‐75] than the 
68% [95% CI: 62‐74; n = 8] inhibition seen for TASK‐3 
channels.
2.2 | Doxapram is a more potent 
inhibitor of mouse TASK‐1 than of mouse 
TASK‐3 channels and mouse TASK‐3/‐1 
heterodimer channels
As the effect of doxapram was different to that demon-
strated on cloned rat channels,15 we looked to determine 
whether the difference observed with human cloned chan-
nels was a species‐dependent effect. To do this, we studied 
the effect of doxapram on cloned mouse channels over a 
range of concentrations. Similar to cloned rat TASK‐1 and 
TASK‐3 channels, TASK‐1 and TASK‐3 channels from 
mouse (mur) were inhibited differentially by doxapram. 
Acute application of doxapram to murTASK‐1 channels at 
a concentration of 1, 3 and 10 µM resulted in current inhibi-
tion of 28% [95% CI: 14‐41, n = 4], 43% [95% CI: 38‐49, 
n = 3] and 58% [95% CI: 50‐66, n = 8], respectively, with a 
calculated 50% effective concentration of 1.5 µM [95% CI: 
0.6‐3.9] (Figure 2A). For murTASK‐3, acute application of 
F I G U R E  1  Effect of doxapram 
on human cloned TASK‐1, TASK‐3 and 
TASK‐2 channels. (A) Concentration‐
response curve for doxapram inhibition of 
human (h) TASK‐1 current. (B) hTASK‐1 
currents evoked by ramp changes in voltage 
in control conditions and in the presence of 
doxapram over a range of concentrations 
(0.3‐100 µM). (C) Concentration‐response 
curve for doxapram inhibition of hTASK‐3 
current. (D) hTASK‐3 currents evoked 
by ramp changes in voltage in control 
conditions and in the presence of doxapram 
over a range of concentrations (0.3‐100 µM). 
(E) A plot of % inhibition by 10 µM 
doxapram from individual cells expressing 
either hTASK‐1, hTASK‐3 or hTASK‐2 
human cDNA. Error bars represent the 95% 
CI. *P < .05, ****P < .0001; One‐way 
ANOVA, followed by a Dunnett's multiple 
comparisons test. (F) Time course plot 
showing the acute application of 10 µM 
Doxapram (blue line) on hTASK‐2 current. 
Each point is a 5 millisecond (ms) average 
of the difference current between that at 
−40 mV and that at −80 mV (see methods 
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doxapram at concentrations of 10 and 100 µM resulted in 
current inhibition of 21% [95% CI: 13‐29, n = 6] and 56% 
[95% CI: 42‐69, n = 6], respectively, with an estimated 50% 
effective concentration ≥100 µM, around 100‐fold higher 
than seen for murTASK‐1 channels (Figure 2B). The inhib-
itory effect of doxapram was significantly smaller at 10 µM 
for murTASK‐3 [P  <  .05, 95% CI of difference: 27‐48], 
compared to murTASK‐1, as was observed with rat TASK 
channels.15
As the predominant channel formed in rat carotid bodies 
are heterodimers of TASK‐1 and TASK‐3,13,14 we also tested 
the effect of doxapram on forced heterodimers of murTASK‐1 
and 3 channels. Combining murTASK‐1 channels with 
murTASK‐3 channels, conferred sensitivity to doxapram. 
Doxapram (10 µM) inhibited murTASK‐3/murTASK‐1 het-
erodimer channels by 42% [95% CI: 29‐56; n = 5], which was 
an intermediary effect between homodimeric murTASK‐1 
(58% [95% CI: 50‐66; n = 8]) and homodimeric murTASK‐3 
(21% [95% CI: 13‐29; n = 6] Figure 2C). Interestingly doxa-
pram (10 µM) inhibited the reverse murTASK‐1/murTASK‐3 
heterodimer channels by 58% [95% CI: 45‐70; n = 5, Figure 
2C,D], which was similar to effects seen on homodimeric 
murTASK‐1 channels (P > .05 [95% CI of difference: −14 
to 16]).
2.3 | The Carboxy terminal domains are 
involved in transducing the effect of doxapram
The difference in sensitivity to doxapram seen between 
rodent TASK‐1 and TASK‐3 channels was suggested to 
occur, although not exclusively, because of structural 
differences between the carboxy terminals of the chan-
nels.15 MurTASK‐1 and TASK‐3 channels share only 50% 
identity, with the least identity occurring in their intra-
cellular carboxy terminal domains. MurTASK‐3 channels 
have many of their regulatory sites, including phospho-
rylation sites located in their C‐terminal domains (Figure 
3A). Removal of the C‐terminus from murTASK‐3 by 
the incorporation of a stop codon at position 250 (Δ250), 
resulted in a functional channel, but with a significantly 
(P < .05, [95% CI of difference: −141 to −91], unpaired 
t test) reduced current of 18 pA pF‐1 [95% CI: −1 to 36, 
n = 5], compared to an average WT current of 134 pA pF‐1 
[95% CI: 110‐158, n = 5], when transfecting 125 ng µL−1 
of DNA. Inhibition of this reduced current by doxapram 
(10 µM) was also severely attenuated (P < .05 [95% CI of 
difference: −27 to −8]) compared to WT (Figure 3B,C). 
Doxapram (10 µM) inhibited murT3_ Δ250 by 4% [95% 
CI: −3 to 10, n = 5, Figure 3B].
F I G U R E  2  Effect of doxapram 
on mouse cloned TASK‐1, TASK‐3 
homodimeric and forced heterodimeric 
channels. (A) Concentration‐response curve 
for doxapram inhibition of murTASK‐1 
current over a range of concentrations 
(0.3‐100 µM). (B) Concentration‐
response curve for doxapram inhibition 
of murTASK‐3 current over a range of 
concentrations (10‐300 µM). (C) A plot 
of % inhibition by 10 µM doxapram 
from individual cells expressing either 
homodimeric murTASK‐3, homodimeric 
murT1, heterodimeric murTASK-3_
murTASK-1 and heterodimeric 
murTASK-1_murTASK-3 cDNA. Error 
bars represent the 95% CI. (D) Raw data 
trace from exemplar mouse heterodimeric 
murTASK-1_murTASK-3 in control (black 
line) and 10 µM doxapram (blue line) using 
a step‐ramp voltage protocol as detailed in 
the Methods
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2.4 | The Carboxy terminal 
domains of human TASK‐1 and TASK‐3 are 
also structurally different, but the effect of 
doxapram is equal
This difference in effect by doxapram on rodent channels, 
if explained by their structurally different carboxy termi-
nals, cannot, however, be easily translated to human chan-
nels as the effect of doxapram on both channels is similar. 
Like rodent channels, human TASK‐1 and TASK‐3 chan-
nels share 58% identity, with the majority of the structural 
dissimilarity occurring at the carboxy terminals of the chan-
nels (see Figure 4A). As seen for murTASK‐3, truncating 
the channel to remove the C‐terminal of the human TASK‐3 
channel (hTASK‐3_Δ250) significantly attenuated the ef-
fect of doxapram (P <  .05 [95% CI of difference: −57 to 
−41], n = 8), with inhibition by 10 µM doxapram reduced 
to 19% [95% CI: 12‐26] (Figure 4B,C). For human TASK‐3, 
F I G U R E  3  Removal of the carboxy terminal of murTASK-3 (murT3) attenuates doxapram effect further. (A) Cartoon to depict the amino 
acid structure of the carboxy terminal of murT3, the location of putative phosphorylation sites and the introduction of the stop codon. (B) Box and 
Whiskers plot of doxapram (10 µM) inhibition of murT3_Δ250 and murT3 wild type. Bars represent the min and max inhibition for each channel 
type. (C) murT3_ Δ250 currents evoked by ramp changes in voltage from −120 to + 20 mV in control conditions (black line) and in the presence 
of 10 µM doxapram (blue line)




























F I G U R E  4  Removal of the carboxy 
terminal of human TASK‐3 attenuates 
doxapram effect. (A) Cartoon to compare 
the identity of the amino acid structure of 
the carboxy terminal of human TASK‐3 
and human TASK‐1. (B) Box and Whiskers 
plot of doxapram (10 µM) inhibition of 
hTASK‐3_Δ250 and WT hTASK‐3. Bars 
represent the min and max inhibition for 
each channel type. (C) hTASK‐3_ Δ250 
currents evoked by ramp changes in voltage 
from −120 to + 20 mV in control conditions 
(black line) and in the presence of 10 µM 
doxapram (blue line)
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truncating the C‐terminus of TASK‐3, significantly 
(P < .05, [95% CI of difference: 40‐87, unpaired t test) in-
creased current to 119 pA pF−1 [95% CI: 88‐151, n = 8], 
compared to an average WT current of 56 pA pF−1 [95% 
CI: 46‐65, n = 16], when transfecting 500 ng µL−1 of DNA. 
Interestingly, current recorded through human TASK‐3 
channels in these experimental conditions is almost eight-
fold smaller than is observed for murTASK‐3 channels.
2.5 | Mutation of identified amino acids 
in the pore region of human TASK channels 
increased channel currents and reduced the 
efficacy of doxapram
Evidence from molecular modelling, docking and aspar-
tate scanning mutagenesis of rat TASK‐1 and TASK‐3, 
using inhibitory compounds such as A1899, PKTHPP and 
doxapram have suggested a common intracellular binding 
site, comprised of hydrophobic residues from the M2 and 
M4 transmembrane domains, within the intracellular pore 
region of these channels.20-22,29 The key amino acids (AA) 
identified are Leucine (L) 122, Glycine (G) 236, L239 and 
Valine (V) 242, which are homologous in the human clones 
(Figure 5A,B). In rat TASK‐3 mutation of these specific AA 
to aspartate (D), considerably affected the efficacy of these 
compounds highlighting the importance of this region for the 
action of these particular compound types.22
We introduced each of the identified AA into human 
TASK‐3 and characterized currents mediated through each 
homodimeric mutated channel (L122D, G236D, L239D and 
V242D). Mutation of either a hydrophobic leucine (L) or a 
small uncharged glycine (G) residue to a charged aspartate 
residue (D), resulted in functional channels with significantly 
(P < .05, one‐way ANOVA followed by a Dunnett's multiple 
comparisons test) increased currents compared to WT (Figure 
6A). The average whole‐cell current measured as a difference 
between current seen at −40 mV and −80 mV was: 56 pA pF−1 
[95% CI: 46‐66, n = 15] for WT; 92 pA pF−1 [95% CI: 81‐102, 
n = 12] for L122D; 131 pA pF−1 [95% CI: 103‐159, n = 7] 
for G236D; 96 pA pF−1 [95% CI: 82‐111, n = 5] for L239D; 
and 118 pA pF−1 [95% CI: 72‐164, n = 6] for V242D, com-
pared with an average whole‐cell current of 2 pA pF−1 [95% 
CI: 1.5‐2.3, n = 5] for cells only transfected with green flu-
orescent protein (GFP), data not shown. All mutated currents 
were outwardly rectifying, with a mean zero current potential 
of −85 mV [95% CI: −88 to −81, n = 12] for L122D; −83 mV 
[95% CI: −86 to −80, n = 7] for G236D; −82 mV [95% CI: 
−87 to −77, n = 5] for L239D) and −83 mV [95% CI: −89 to 
−77, n = 6] for V242D, compared with −31 mV [95% CI: −43 
to −20, n = 5] for GFP‐only cells. None of the zero current 
potentials for the mutant channels were significantly different 
(P > .05) from WT which was −82 mV [95% CI: −85 to −79, 
n = 15] (Figure 6B). We then tested whether these mutations 
modified the potency of doxapram, as had been observed in rat 
channels.22 All four mutations significantly reduced (P < .05) 
doxapram potency, with the largest reduction in effect observed 
with the L122D mutation (Figure 6C,D). The percentage in-
hibition was 6% [95% CI: 3‐9, n = 10] for L122D; 26% [95% 
CI: 15‐36, n = 8] for G236D; 13% [95% CI: 6‐20, n = 8] for 
L239D; and 27% [95% CI: 13‐41, n = 5] for V242D compared 
to 62% [95% CI: 57‐67, n = 16] for WT. To further confirm the 
consensus that doxapram acts within the intracellular pore of 
TASK channels,15 we studied the effect of another well‐known 
TASK‐3 inhibitor, zinc, which is proposed to have its mode of 
action from the extracellular side of the channel.30,31 Using the 
aspartate mutant channel, L122D, we found that the effect of 
zinc, was not affected (P > .05 [95% CI of difference: −17 to 
3]) by this pore mutation, with 100 µM zinc giving an inhibition 
F I G U R E  5  Computer homology 
model of human TASK‐3 channel with 
indicated putative binding site. (A) 
Homology model of human TASK‐3 
channel based upon TRAAK crystal 
structure (PDB ID 3UM7)54 depicting 
location of the four amino acids (AA) that 
form the putative site, L122, G236, L239 
and V242 (shown with arrows) as viewed 
from beneath the channel. (B) AA sequence 
alignment of human TASK‐1 and TASK‐3. 
Dashes represent gaps in the sequence 
and numbers represent the position of the 
starting AA. The black box highlights the 










   | 7 of 13CUNNINGHAM et Al.
of 87% [95% CI: 76‐98, n = 5], compared with 94% [95% CI: 
90‐98, n = 5] for WT TASK‐3 (Figure 6 E,F).
2.6 | Enantomeric separation of 
doxapram reveals a stereoselective effect on 
TASK channels
Doxapram is a racemic compound that can be chirally sepa-
rated into a (+)—enantiomer (GAL‐054) and (−)—enantiomer 
(GAL‐053) (Galleon Pharmaceuticals Inc).27 The eutomer 
(GAL‐054) was found to be a superior respiratory stimulant 
compared to doxapram when tested in animal models, whilst 
the distomer (GAL‐053) was markedly inferior.24-26 We looked 
to see what effect these separate enantiomers of doxapram 
had on human TASK‐1 and TASK‐3 current. Compared with 
doxapram and GAL‐053, GAL‐054 was twice as potent as 
doxapram with EC50s of ~1.6 and 1.4 µM for human TASK‐1 
and TASK‐3 respectively. GAL‐053 had reduced potency on 
F I G U R E  6  Pore‐lining residues of the M2 and M4 domains are influenential for doxapram inhibition of the human TASK‐3 channel. (A) 
graph of current density (pA pF‐1) measured from individual cells transiently expressing WT TASK‐3, TASK‐3_L122D, TASK‐3_G236D, 
TASK‐3_L239D, TASK‐3_V242D. Error bars represent the 95% CI and * statistical significance (*P < .05; ****P < .0001). (B) A plot of zero 
current level (mV) measured from individual cells transiently expressing WT TASK‐3, TASK‐3_L122D, TASK‐3_G236D, TASK‐3_L239D, 
TASK‐3_V242D. Error bars represent the 95% CI. (C) Box and Whiskers plot of doxapram (10 µM) inhibition of WT TASK‐3, TASK‐3_L122D, 
TASK‐3_G236D, TASK‐3_L239D and TASK‐3_V242D. Bars represent the min and max inhibition for each channel type. (D) hT3_ L122D 
currents evoked by ramp changes in voltage from −120 to + 20 mV in control conditions (black line) and in the presence of 10 µM doxapram (blue 
line). (E) Box and Whiskers plot of zinc (100 µM) inhibition of WT TASK‐3 and TASK‐3_L122D. Bars represent the min and max inhibition for 
each channel type. (F) hT3_ L122D currents evoked by ramp changes in voltage from −120 to + 20 mV in control conditions (black line) and in 
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TASK‐1 and TASK‐3, with EC50s ~336 and 286 µM respec-
tively. Acute application of 1, 3 and 10 µM GAL‐054 to human 
TASK‐1 expressing tsA201 cells, resulted in an inhibition of 
45% [95% CI: 37‐53, n = 6]; 54% [95% CI: 52‐57, n = 5]; and 
75% [95% CI: 71‐79, n = 6] respectively. For human TASK‐3 
inhibitions of 43% [95% CI: 30‐56, n  =  6]; 66% [95% CI: 
61‐72, n = 5]; and 79% [95% CI: 73‐84, n = 8] were seen for 
the same concentrations (Figure 7A‐D). Acute application of 
10, 100 and 300 µM GAL‐053 to human TASK‐1, resulted in 
an inhibition of 3% [95% CI: −9 to 15, n = 6]; 24% [95% CI: 
13‐35, n = 5] and 47% [95% CI: 38‐56, n = 5]. For human 
TASK‐3 inhibitions of 8% [95% CI: 5‐12, n = 6]; 35% [95% 
CI: 31‐38, n = 6] and 50% [95% CI: 43‐56, n = 5] were seen 
for the same concentrations (Figure 7E‐H).
3 |  DISCUSSION
Doxapram is one of the few respiratory stimulants still in 
clinical use and has been shown to inhibit cloned rat TASK 
F I G U R E  7  The (+)—enantiomer 
(GAL‐054) is responsible for the inhibitory 
effects observed with doxapram on human 
TASK channels. (A) A plot of % inhibition 
of 1, 3 and 10 µM GAL‐054 on human 
TASK‐1 channels. Each point represents an 
individual cell and the error bars represent 
the 95% CI. (B) human TASK‐1 currents 
evoked by ramp changes in voltage from 
−120 to + 20 mV in control conditions 
(black line) and in the presence of 10 µM 
GAL‐054 (red line). (C) A plot of % 
inhibition of 1, 3 and 10 µM GAL‐054 
on human TASK‐3 channels. (D) human 
TASK‐3 currents in control conditions 
(black line) and in the presence of 10 µM 
GAL‐054 (red line). (E) A plot of % 
inhibition of 10, 100 and 300 µM GAL‐053 
on human TASK‐1 channels. (F) human 
TASK‐1 currents in control conditions 
(black line) and in the presence of 10 µM 
GAL‐053 (green line). (G) A plot of % 
inhibition of 10, 100 and 300 µM GAL‐053 
on human TASK‐3 channels. (H) human 
TASK‐3 currents in control conditions 
(black line) and in the presence of 10 µM 
GAL‐053 (green line). The specificity 
observed with mouse TASK channels 
remained unchanged with for the (+)—
enantiomer GAL‐054, with the enantiomer 
being twice as potent on murTASK‐1 
channels compared with murTASK‐3 (data 
not shown). A concentration of 10 µM 
inhibited murTASK‐1 channels by 63% 
[95% CI = 61 to 65, n = 3] compared to 































































–100 –80 –60 –40 –20 20
































–120–100 –80 –60 –40 –20 20



















































































(A)  hTASK-1 (B)
(E) hTASK-1 (F)
   | 9 of 13CUNNINGHAM et Al.
channels and native TASK channels (TASK‐1/3 heterodimers) 
in rat type 1 cells5,15,16,22 with highest potency observed for 
rat TASK‐1 (TASK‐1 > TASK‐1/3 heterodimer > TASK‐3).
The mode of action by which doxapram acts as a respi-
ratory stimulant in humans is controversial. In part, this is 
a consequence of differing effects observed in various ani-
mal models. In particular, the stated molecular mechanism 
by which doxapram has its effect, has been characterized en-
tirely in rodents.5 In this study, we characterized the effect of 
doxapram on cloned human TASK channels (TASK‐1 and 
TASK‐3), to give a better understanding of the pharmacolog-
ical profile of this drug in humans, and any potential clinical 
consequences for patients.
Interestingly, we have found that doxapram is an equally 
potent inhibitor of both human TASK‐1 and TASK‐3 chan-
nels, which is different to that seen previously in rat chan-
nels, where the drug is 90‐fold more potent on TASK‐1 
or heteromultimers of TASK‐1 and TASK‐3 than on 
TASK‐3.15,22 We investigated whether this was a species 
dependent effect by repeating the same experiments on 
cloned mouse TASK channels and found, as for rat chan-
nels, that doxapram was a more potent inhibitor of mouse 
TASK‐1 channels and heteromultimers of these channels, 
than mouse TASK‐3 channels.
The increased potency of doxapram for TASK‐3 channels 
may not alter the determined molecular mechanism by which 
doxapram has its effect on TASK channels in the carotid bod-
ies, as heteromultimers of TASK‐1 and TASK‐3 are the pre-
dominant channel in these type 1 cells, at least for rodents.13,14 
Its inhibitory effect on human TASK‐3 channels may how-
ever, contribute to the side effect profile of this compound, 
in humans. For example, changes in systolic blood pressure 
have been linked to changes in TASK‐3 channel expression.32 
Indeed, some of the major limitations to doxapram's clinical 
use has been its analeptic and pressor effects, which includes 
an increase in arousal, panicogenic activity, increased hy-
perventilation, increased blood pressure and heart rate, and 
convulsions, in patients.27,33 Many of these side effects are 
observed primarily in patients that already suffer from these 
conditions and typically are manifest during continuous intra-
venous infusion, due the compounds short half‐life.34
We also show that the effect of doxapram is restricted to the 
TASK family of channels, with the compound having no ef-
fect on a closely related channel member, TASK‐2. However, 
inhibitory effects have been observed with TASK‐2 at much 
higher concentrations of doxapram (300 µM and 1 mM).15
Removing the C‐terminus of TASK‐3 channels, both for 
murine and human TASK‐3 channels, significantly reduces 
the effectiveness of doxapram (Figures 3B and 4B). This 
correlates with earlier experiments in rat cloned channels, 
where C‐terminal domain swopping of TASK‐1 to TASK‐3, 
increased or decreased the sensitivity of the channels to doxa-
pram15 and reduced the effectiveness of the endocannabinoid, 
methanandamide.35 The rationale for the earlier experiments, 
was because of the high sequence dissimilarity between ro-
dent TASK‐1 and TASK‐3 C‐termini. However, for human 
channels, the potency of doxapram is equal, despite the same 
high sequence dissimilarity in the C‐termini between the two 
channels (Figure 4A), making the importance of the C‐termini 
harder to interpret. Because of the importance of this region 
for signalling inputs, such as phosphorylation,36 one can hy-
pothesize that the phosphorylation state of the channel may be 
important for doxapram's effect, particularly as the number of 
putative phosphorylation sites are different between TASK‐1 
and TASK‐3, with more predicted sites on mouse and human 
TASK‐3.37 For human TASK‐3 channels, C‐terminal trunca-
tion resulted in a two-fold increase in current. By truncating 
the channel, it is possible that the channel has been pushed 
into an open state, perhaps by locking the channel into a par-
ticular phosphorylation state, or because gating at the selec-
tivity filter is disrupted by C‐terminus truncation. Indeed, for 
known gain‐of‐function mutations on these channels and other 
related K2P channels, regulation by blockers or activators is 
modified when the link between the C‐terminus and the selec-
tivity filter is disrupted.37,38 Surprisingly, however, truncation 
of murTASK‐3 channels, resulted in a significant reduction in 
current recorded through these channels, but this still attenu-
ated the effect of doxapram. With the structure of the intracel-
lular C‐termini of K2P channels not determined by existing 
crystal structures, the involvement of this region remains diffi-
cult to evaluate. The C‐terminal domain of another potassium 
channel, GIRK2, has been resolved by crystallography and 
this shows that for this particular channel, the C‐terminal acts 
as an additional gate to regulate pore access.39
Recent molecular modelling studies of rat TASK‐1 and 
rat TASK‐3 channels using TASK selective inhibitory com-
pounds such as A1899, PKTHPP, ML365 and doxapram, 
have suggested a common intracellular binding site, within 
the pore region of these channels.20-22 To further elucidate 
the molecular mode of action of doxapram on human chan-
nels, we examined previously identified hydrophobic residues 
in rat, located on the M2 and M4 transmembrane regions of 
TASK‐3, that face the pore region of the channel. These res-
idues are suggested to form a common intracellular binding 
site for a number of respiratory stimulants, including doxa-
pram. In particular, mutation of a leucine (L) on the M2 re-
gion, L122, and another on the M4 region, L239, significantly 
attenuates doxapram effect. It has previously been suggested 
that L122 and L239, create a hydrophobic narrowing of the 
pore, which affects the potency of three breathing stimulants, 
PKTHPP, A1899, and doxapram.22 When these normally 
hydrophobic residues are mutated to hydrophilic (lipid‐re-
pelling) residues, such as aspartate residues, this creates a 
barrier in the pore, because of either an increase in water and 
potassium ion occupancy in the pore and/or this region acts 
as a fulcrum point for channel gating, preventing access of 
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the drug.22 This correlates with another previous molecular 
modelling study of doxapram, which suggests the drug has 
a high affinity for a hydrophobic cleft in which to bind40 and 
with a study conducted on TASK‐3_L122D, which suggested 
that mutating this amino acid to an aspartate produces a fixed 
open conformation that reduces the effects of anaesthetics.29 
As well as for doxapram22 the L239 residue has previously 
been identified in TASK‐1 for its involvement in A1899 inhi-
bition20 and more recently in A293 inhibition.41
In our experimental conditions, the currents recorded 
through all four mutant channels (L122D, G236D, L239D 
and V242D) are significantly larger than for WT channels, 
suggesting that the channel may be gated into an open con-
firmation, reducing the efficacy of inhibitors, such as doxa-
pram, similar to that seen with the T3_Δ250 channel.
For L122D in particular, the mutation that caused the most 
dramatic reduction in doxapram effect, it has recently been 
shown that D or N mutations at this position in all K2P chan-
nels act as gain of function mutations42 and mutations at this 
position alter the effectiveness of a number of K2P channel 
regulators.42,43 This may confound interpretation of functional 
experiments that suggest this residue is involved in regulator 
binding. To address this, we investigated whether this partic-
ular mutation attenuated the effect of another known TASK‐3 
antagonist, zinc, which has been shown to act on residues on 
the extracellular side of the channel.30,31 This mutation had no 
effect on zinc inhibition of the channel, which is in agreement 
with the hypothesis that doxapram does indeed act at a site 
within the intracellular pore region of the channel.22
Since the submission of this manuscript a crystal structure 
of TASK‐1, bound to inhibitory compounds, was released.44 
The resolved structure, revealed the presence of a unique 
gate, termed “X‐gate”, at the intracellular entrance to the ves-
tibule, formed from a conformational rearrangement of the 
M4 helices, involving the VLRFMT region. For two novel 
inhibitory compounds (BAY 1000493 and BAY 2341237) 
it was shown that the compounds bind within an inner ves-
tibule, directly below the selectivity filter. Consistent with 
previously published work,20,22,40,41 L122 and L239, along 
with some other amino acids, were important for binding 
and trapping of these inhibitory compounds, within TASK‐1 
channels. In particular, they found that L122 projected into 
the vestibule below the compounds, holding them in place 
and this was thought to be responsible for the slow compound 
washout rates observed for these and others compounds.15 
Indeed, we also observed that for TASK‐1, washout of doxa-
pram, was slow and often incomplete, however, this was not 
true for TASK‐3. This suggests that despite high sequence 
similarity between TASK‐1 and TASK‐3 in this region, the 
arrangement of amino acids within the vestibule and the X‐
gate (VLRFMT for TASK‐1, but VLRFLT for TASK‐3) may 
differ slightly between the two channels and perhaps also for 
heterodimers of the channels.
Interestingly, another putative doxapram binding residue, 
G236, is mutated to a large positively charged arginine (R) in a 
condition known as Birk Barel Mental Retardation Syndrome 
or more recently, KCNK9 Imprinting syndrome.23,45 In this 
homodimeric conformation the channel is poorly function-
ing, with low current levels, which are inwardly rectifying 
and show altered potassium selectivity.46 When G236 is mu-
tated to an aspartate, however, the current is significantly in-
creased through these channels, remains outwardly rectifying 
and potassium selective.
We have also shown that chiral separation of doxa-
pram into its positive and negative enantiomers, results in 
a highly potent inhibitory eutomer (GAL‐054), which was 
twofold more potent than doxapram and a poorly inhibitory 
distomer (GAL‐053) when tested on human cloned channels, 
transiently expressed in a human tsA201 cells. These data 
correlate nicely with pre‐clinical data in opioid challenged 
rats and cynomolgus monkeys, where GAL‐054, dose‐de-
pendently increased minute volume when administered in-
travenously, whilst GAL‐053, had no effect.24-26 It was also 
observed in these studies that some of the known side‐effects 
of this drug, were restricted to the distomer, raising hope 
for an improved ventilatory stimulant, with few side effects. 
Disappointingly, the known pressor effects of doxapram in 
human and dogs47,48 were still evident with GAL‐054. In 
conscious rats and in healthy human volunteers of a Phase 1 
clinical trial. GAL‐054 was found to increase blood pressure 
by 15%‐20% (unpublished data, Galleon Pharmaceuticals)27 
and consequently was no longer pursued because of patient 
safety concerns. It has been suggested that this observed in-
crease in blood pressure may occur because of an increase in 
catecholamine levels during administration of doxapram.49 
As the proposed mechanism of action by which doxapram 
reverses respiratory depression is via the direct stimulation 
of peripheral chemoreceptors of type 1 cells within the ca-
rotid bodies, resulting in a subsequent release of catechol-
amines.4,50 It remains possible that any drugs that target 
TASK channels in carotid bodies, may also increase blood 
pressure. It should also be borne in mind that the hemo-
dynamic reflex response to selective stimulation of carotid 
body chemoreceptors is complex and often described as con-
text specific, and that evoked ventilatory stimulation can be 
associated with early pressor and later depressor effects.51-53
In our study, all experiments were performed using human 
cell lines in normoxic conditions at room temperature. Whilst 
this gives consistency of basal responses on which to measure 
the effects of doxapram, it is also a limitation as we did not in-
vestigate the effects of doxapram under conditions of hypoxia, 
which causes an inhibition of both TASK‐1 and TASK‐3 chan-
nels, or at normal body temperature. In clinical conditions, dox-
apram is often used in hypoxic conditions and always at body 
temperature, which makes it less easy for us to extrapolate ef-
fects seen in our controlled cell systems to clinical situations.
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Nevertheless, the data reported here showing that the effect 
on TASK channels is restricted to the positive enantiomer; the 
differential potencies between human and murine channels and 
the molecular information regarding a potential intracellular 
binding site within the pore region of TASK channels, will be of 
benefit for the design of new therapeutic molecules with higher 
potency, higher specificity and fewer associated side effects.
4 |  MATERIALS AND METHODS
4.1 | Molecular biology
Murine (mur) wild‐type (WT) TASK‐1 (KCNK3, GenbankTM 
DQ185133) and WT murTASK‐3 (KCNK9, GenbankTM 
AH009585.2) cDNA were cloned into pCS2+ vector and 
were a kind gift from William Wisden (Imperial College, 
UK). Human WT TASK‐1 (GenbankTM AF006823.1), 
WT TASK‐3 (GenbankTM AF212829) and WT TASK‐2 
(KCNK5, GenbankTM AF084830.1) cDNA’s, were cloned 
into pcDNA3.1+ vector (Invitrogen) and were a kind gift 
from Helen Meadows (GlaxoSmithKline).
4.2 | Mutations
Point mutations (L122D, G236D, L239D, V242D or a stop 
codon) were introduced by site‐directed mutagenesis into 
TASK‐3 cDNA using the Quikchange kit (Stratagene) as 
previously described.54
4.3 | Cell culture
All experiments were performed using a modified human 
embryonic kidney 293 cell line, tsA201 (ECACC; Sigma‐
Aldrich), prepared and maintained as previously described.54
4.4 | Transfection
For the electrophysiological experiments, cells were tran-
siently transfected using a modified calcium phosphate 
protocol, following a process as previously described.54 
Vectors cloned with the gene of interest and a similar vec-
tor encoding the cDNA for GFP were added to each well at 
a concentration of 0.5 µg per well, with the exception being 
for murTASK‐3, where 0.125 µg per well was used.
4.5 | Whole‐cell patch clamp 
electrophysiology
Currents were recorded from tsA201 cells transiently trans-
fected with the channel of interest using whole‐cell patch 
clamp in a voltage clamp configuration and a step‐ramp 
voltage protocol as previously described.54 Briefly, all ex-
periments were conducted at room temperature (20‐24°C) 
using an external solution composed of 145 mM of NaCl, 
2.5  mM of KCL, 3  mM of MgCl2, 1  mM of CaCl2 and 
10 mM of HEPES (pH 7.4, using NaOH) and an intracel-
lular pipette solution composed of 150 mM of KCL, 3 mM 
of MgCl2, 5 mM of EGTA and 10 mM of HEPES (pH ad-
justed to 7.4 with KOH). External solution and modulatory 
compounds were superfused at a rate of 4‐5  mL  min−1. 
Currents were recorded using an Axopatch 1D patch clamp 
amplifier (Molecular Devices), filtered at 0.3  kHz, digi-
tized at 1 kHz.
4.6 | Data analysis and statistics
For analysis of outward current, we measured the current differ-
ence between the −80 and −40 mV. The current‐voltage graphs 
were obtained from the ramp change in voltage between −120 
and +20 mV. For each cell, the current amplitude (pA) was nor-
malized to the cell capacitance (pF). The currents obtained were 
analysed using pCLAMP 10.2 software (Molecular Devices), 
Microsoft Excel and GraphPad Prism 6 or 7 software. Data 
were expressed as the mean ± 95% Confidence Intervals (CI), 
and n represents the number of individual cells. For EC50 cal-
culations, concentration‐response curves were fitted using the 
Hill equation. Statistical analysis used were one‐way ANOVA 
with a post‐hoc Dunnett's test or an unpaired/paired Student's t 
test. Data were considered statistically different if P < .05. The 
data and statistical analysis comply with the recommendations 
on experimental design and analysis in pharmacology.55
4.7 | Chemicals
Doxapram, GAL‐053 and GAL‐054 were a kind gift of 
Galleon Pharmaceuticals Inc and were prepared in water to 
create 10 mM stock solutions that were then diluted, in ex-
ternal solution, to desired concentration just before use. Zinc 
Chloride was purchased from Sigma‐Aldrich and was made 
up in water to create a 100 mM stock.
4.8 | Homology modelling
hTASK-3 (UniProtKB/Swiss‐Prot ID Q9NPC2) and murTASK-3 
(UniProtKB/Swiss‐Prot ID Q3LS21) homology models were 
developed as previously described45 using Modeller 9v8.56 
The human TWIK‐related arachidonic acid activated K 
(TRAAK) structure (PDB ID 3UM7)57 was used as a tem-
plate for TASK-3 modelling, ClustalW58 was used to align 
the TRAAK and TASK-3 sequences.
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